Inovio Pharmaceuticals (NASDAQ:INO) Announces Quarterly Earnings Results

Inovio Pharmaceuticals (NASDAQ:INO) released its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.68, FiscalAI reports. The business had revenue of ($0.07) million during the quarter, compared to the consensus estimate of $0.33 million.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• BLA accepted: The BLA for INO-3107 was accepted for review under the Accelerated Approval Program with a standard 10‑month review and a PDUFA target date of October 30, 2026, and the filing is under active review.
• FDA raised a preliminary concern that Inovio did not provide adequate information to justify Accelerated Approval eligibility; Inovio has submitted additional documentation (an assessment aid/sBLA) and is awaiting a meeting date with the agency.
• Cost reductions (≈15% headcount cut, rescoping) and spending prioritization extended the company’s estimated cash runway into Q4 2026; cash and short‑term investments were $58.5M at year‑end and Q1 operational net burn is expected to be ≈$22M.
• Company continues to advance its platform via partnerships and programs (Dana‑Farber/Akeso phase 2 adaptive GBM trial for INO‑5412, DPROT and dMAb progress) while keeping most resources focused on a potential INO‑3107 launch.

Inovio Pharmaceuticals Stock Down 1.2%

INO stock traded down $0.02 during trading on Friday, reaching $1.66. The stock had a trading volume of 923,660 shares, compared to its average volume of 746,348. The company has a market capitalization of $110.77 million, a price-to-earnings ratio of -0.99 and a beta of 1.70. Inovio Pharmaceuticals has a one year low of $1.30 and a one year high of $2.98. The company’s 50 day moving average is $1.65 and its two-hundred day moving average is $2.05.

Inovio Pharmaceuticals News Roundup

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: BLA accepted under the FDA’s Accelerated Approval Program for INO‑3107 (potential RRP treatment); PDUFA date set for Oct. 30, 2026 — a clear regulatory milestone that could materially de‑risk and create commercial value if approved. INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Q4 2025 results showed a surprising EPS beat (reported $0.31 vs. consensus ~($0.37)), which reduces short‑term earnings uncertainty. The company also highlighted published clinical/immunology data and advancing next‑generation DNA medicine technologies (DMAbs, DPROT). INOVIO Reports Fourth Quarter and Full Year 2025
• Neutral Sentiment: Management discussed strategic moves and regulatory planning on the Q4 earnings call; investors should listen for commercialization plans, cash‑burn guidance, and timelines for INO‑3107 ahead of the October PDUFA. Earnings Call Highlights
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff actions alleging securities fraud for the Oct. 10, 2023–Dec. 26, 2025 class period; several reminders cite an April 7, 2026 deadline — this legal overhang increases litigation risk, potential settlement exposure, and headline volatility. Representative notices: Glancy Prongay Wolke & Rotter and Schall Law Firm. Deadline Alert: Glancy Prongay Wolke & Rotter Schall Law Firm Notice
• Negative Sentiment: Revenue metrics missed expectations (press coverage shows revenue below consensus), and sell‑side models still forecast a negative FY EPS (analyst consensus cited ~‑4.23), implying continued cash‑flow and financing risk that could dilute shareholders. MarketBeat INO snapshot
• Negative Sentiment: Technical/market context: the 50‑day moving average sits below the 200‑day, and volume is below average — factors that can amplify downside during negative headlines. Interactive Chart

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of INO. Focus Partners Wealth bought a new position in shares of Inovio Pharmaceuticals in the third quarter valued at approximately $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Inovio Pharmaceuticals by 39.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 5,894 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Inovio Pharmaceuticals by 752.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 18,160 shares during the period. Raymond James Financial Inc. grew its stake in Inovio Pharmaceuticals by 4,396.0% in the 3rd quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 16,309 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter valued at $41,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Analyst Upgrades and Downgrades

INO has been the topic of a number of analyst reports. HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, December 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research note on Monday, December 29th. Piper Sandler reissued an “overweight” rating and set a $6.00 price objective (up from $5.00) on shares of Inovio Pharmaceuticals in a report on Friday, November 14th. UBS Group reissued an “overweight” rating on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. Finally, Oppenheimer restated an “outperform” rating on shares of Inovio Pharmaceuticals in a report on Friday. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Inovio Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $6.75.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.